•  Nasdaq

  •  OTC BB

  •  
     

    GlaxoSmithKline (GSK) Gets FDA Approval for Raxibacumab Anti-Toxin for the Treatment of Inhalational Anthrax

    December 15 Dec 2012 | 11:05
     

    crwenews

     

     

    http://pennyomega.com/img/gsk.jpg GSK, GlaxoSmithKline plc

     

    ** GSK reported that the U.S. Food and Drug Administration (FDA) has approved raxibacumab for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.

    The effectiveness of raxibacumab is based solely on efficacy studies in animal models as it is not ethical or feasible to conduct controlled clinical trials with intentional exposure of humans to anthrax.

    The safety of raxibacumab has been studied in healthy adult volunteers, however, there have been no studies of raxibacumab in the pediatric population.

    Raxibacumab is the first monoclonal anti-toxin to be approved for inhalational anthrax. Anthrax is a rare and lethal disease, caused by a toxin producing bacterium.

    While antibiotics target the anthrax bacteria, raxibacumab offers an additional mechanism by blocking the activity of the anthrax toxin, which plays a key role in the progression of the disease.

    http://pennyomega.com/img/gsk_chart.jpg

    GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

    More about GSK at www.gsk.com

    ******************

    Read Full Disclaimer at http://CRWENews.com/disclaimer


    Tags: , ,

     
    Share/Bookmark
     


     






     
     
     CRWE Network